Reactive oxygen species (ROS) are produced by dendritic cells (DCs) during antigen presentation in contact hypersensitivity (CHS). ROS cause a number of non-enzymatic protein modifications, such as carbonylation. Carbonylated proteins in DCs in response to hapten have not been fully identified yet. To identify the proteins carbonylated by ROS, murine epidermis-derived DC line XS106 was challenged with a hapten, 2,4,6-trinitrobenzene sulphonic acid (TNBS). MALDI-TOF analysis revealed that heat-shock protein 70 (HSP70) was one of the carbonylated proteins induced by TNBS. To verify the role of HSP70 in TNBS-treated XS106 cell, we fused protein transduction domain (PTD) with HSP70 to facilitate protein delivery into the cell. The transfected fusion protein HSP70 within the cell caused transient increase of the cellular level of HSP70. Transient increase of HSP70 level in XS-106 DCs resulted in inhibition of ROS production, carbonylation of HSP70, p38 MAPK activation and subsequently IL-12 secretion. To investigate the effects of PTD-HSP70 in vivo, ear-swelling experiments with 2,4,6-trinitro-1-chlorobenzene (TNCB) were performed in BALB/c mice. Pretreatment of PTD-HSP70 reduced the CHS response to TNCB in vivo. We report here that carbonylation of HSP70 by ROS is associated with the pathogenesis of CHS, suggesting possibility of HSP70-targeting therapy in CHS.
Introduction
Skin dendritic cells (DCs) play a central role in the initiation of allergic skin responses. With allergen stimulation, DCs differentiate into immunostimulatory DCs, which are able to present antigens effectively to T cells [1, 2] . During antigen presentation, DCs produce reactive oxygen species (ROS) [2] .
Reactive oxygen species cause cellular damage by oxidative stress [3] . ROS, however, have essential and beneficial roles in intracellular signal transduction and in defence against micro-organisms [4] . The carbonylation of proteins is one of the most widely used biomarkers for oxidative damage to cells [5, 6] . A well-characterized contact allergen, 2,4,6-trinitrobenzene sulphonic acid (TNBS), induces ROS production in DCs. We previously reported that the level of carbonylation of mitochondrial ATP synthase was increased by ROS in TNBS-treated XS-106 DCs [7] . Carbonylated mitochondrial ATP synthase was further metabolized and degraded. Degradation of mitochondrial ATP synthase caused ROS overproduction, which then resulted in immune stimulation by IL-12 production [7] . Thus, we reported that TNBS-induced ROS may act as a secondary messenger for immune stimulation in XS-106 DCs.
In this study, we identified HSP70 as another target protein for carbonylation by ROS in TNBS-treated XS-106 DCs. Transient overexpression of HSP70 caused decreased production of ROS, IL-12 and p38 MAPK in TNBS-treated XS-106 DCs. Pretreatment with HSP70 diminished the earswelling response in a murine model of contact hypersensitivity (CHS) induced by 2,4,6-trinitro-1-chlorobenzene (TNCB). Suppression of the CHS response by HSP70 may provide a novel approach for treatment of CHS in the future.
Materials and methods
Cell culture. The XS-106 DC line, provided by Professor Akira Takashima (University of Toledo College of Medicine, Toledo, OH, USA), is a long-established DC line derived from the epidermis of newborn A/J mice, and its phenotypic and functional features are described elsewhere [8, 9] . XS-106 DCs were grown in complete RPMI-1640 supplemented with 1 ng/ml murine GM-CSF (BD Pharmingen, San Diego, CA, USA) and 10% NS47 fibroblastconditioned medium.
Cell viability assay. XS-106 DCs were seeded in 96-well plates. One day after seeding, the cells (5 9 10 5 cells/ml) were incubated with TNBS for 24 h and then stained with PI/annexin V-FITC (Annexin-V-FITC kit; Beckman Coulter, Roissy, France). Apoptotic cells and necrotic cells were quantified by flow cytometer (FACSCalibur; Becton Dickinson, Mountain View, CA, USA).
Flow cytometric analysis of ROS in XS-106 DCs. To determine whether DCs produce ROS during TNBS stimulation, we treated XS-106 DCs with 50 lg/ml TNBS (Sigma-Aldrich, St. Louis, MO, USA) for 15 min and added 10 lM 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate (CM-H 2 DCFDA; Molecular Probes Inc., Eugene, OR, USA), an oxidation-sensitive dye. After additional incubation for 15 min, samples were washed and analysed by flow cytometry (FACSCalibur) and FlowJo software (Tree Star, Ashland, Jackson, OR, USA) for fluorescence signals within the PI À populations.
Western blotting. Western blotting was carried out with 30 lg of protein from whole-cell lysates of XS-106 DCs. Proteins were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corporation, Bedford, MA, USA) and detected using ECL (Amersham Biosciences, Piscataway, NJ, USA). The anti-2,4-dinitrophenol (anti-DNP; Cell Signaling, Beverley, MA, USA), anti-mouse HSP70 and anti-p38 MAPK antibodies (Sigma-Aldrich) were used at a dilution of 1:5000. To detect protein carbonylation in XS-106 DCs using one-dimensional gel electrophoresis, 10 ll of DNP solution (Cell Signaling) was added to the cell lysates. The sample was incubated at room temperature for 15 min and neutralized with 7.5 ll of neutralization solution (Cell Signaling) for DNP before conducting gel electrophoresis. An anti-actin antibody (Sigma-Aldrich) was used as a control at 1:5000.
Gel staining and MALDI-TOF mass spectrometry. After XS-106 DCs were treated with 50 lg/ml TNBS for 6 h, 30 lg of whole-cell extracts were separated by electrophoresis and stained with colloidal Coomassie blue (Novex, San Diego, CA, USA) for 24 h. Gels were destained with H 2 O and scanned on an Epson Expression 1600 proscanner (Epson, Long Beach, CA, USA), and the band pattern was analysed using Phoretix gel analysis software (Nonlinear Dynamics, Newcastle, UK).
To examine DNP-modified proteins in the immunoblots, interesting protein bands were excised. Each excised protein band was placed in a polypropylene tube, cut into smaller pieces, and digested using trypsin (Promega, Madison, WI, USA), as previously described [10] . For MALDI-TOF mass spectrometry analysis, the tryptic peptides were concentrated on POROS R2 and R3 oligo columns (Applied Biosystems, Foster City, CA, USA). Samples were applied to R2 columns washed with 40% methanol, 100% acetonitrile, and 50 mM ammonium bicarbonate and then eluted in 2 ml of a-cyano-4-hydroxycinnamic acid before MALDI-TOF analysis [11] . Spectra were obtained using a 4800 TOF/TOF spectrophotometer (Applied Biosystems). Protein database searching was performed using the MSFit program (http:// prospector.ucsf.edu/prospector/mshome.htm) with monoisotopic peaks. An initial mass tolerance of 50 ppm was used. With identified proteins, the machine was recalibrated at 20 ppm. Spectra were also internally calibrated using trypsin autolysis products, and the resulting peptide masses were compared with values in databases managed by the National Center for Biotechnology Information (http:// www.ncbi.nlm.nih.gov).
Expression and purification of cell-permeable HSP70 proteins. To validate the role of HSP70 in TNBS-treated XS-106 DCs, we used a cell-permeable protein transduction domain (PTD; YARVRRRGPRR) from the human transcriptional factor Hph-1. The cell-permeable, PTD-HSP70 fusion protein was provided by Professor Sang-Kyou Lee (Yonsei University, Seoul, Korea). The methods used for construction and purification of Hph-1-fusion protein are described elsewhere [12, 13] . Briefly, BL21 (DE3) Escherichia coli (Molecular Probes Inc.) were transformed with plasmids encoding the PTD-HSP70 fusion protein. The expression of HSP70 protein was induced for 4 h at 37°C by addition of 1 mM isopropylb-D-thiogalactopyranoside. Cells were harvested by centrifugation and sonicated in lysis buffer (50 mM NaH 2 PO 4 , 10 mM imidazole, 300 mM NaCl, pH 8.0). Cellular lysates were resolved by centrifugation (9,600 g for 20 min at 4°C) and loaded onto a Ni-NTA column (Qiagen, GmbH, Hilden, Germany). Bound proteins were washed and eluted with 50, 100 and 250 mM, or 3 M imidazole with >95% purity. The eluted proteins were desalted using PD-10 Sephadex G-25 (Amersham Pharmacia, Piscataway, NJ, USA), supplemented with 10% glycerol, aliquoted and flash-frozen at À80°C [14] .
To determine the protein transduction efficiency of cellpermeable HSP70, XS-106 DCs were cultured with 2 lM cell-permeable HSP70 for 1-12 h, and whole proteins were extracted for immunoblotting with anti-HSP70 antibody.
Cytokine detection. The levels of IL-12 were measured in the supernatants of XS-106 DCs by ELISA using matchpaired specific antibodies against IL-12p70 (BD OptIEA mouse ELISA kit; BD Biosciences, San Jose, CA, USA), according to the manufacturer's protocol.
Glutathione measurement in TNBS-treated XS-106DCs. The Glutathione (GSH) content of cells was determined using assay kits (Biovision, Research Products, Mountain View, CA, USA). The GSH kit utilizes an enzymatic recycling method based on the reaction between GSH and 5, 5-dithiobis (2-nitrobenzoic acid; DTNB) that produces a yellow-coloured compound, 5-thio-2-nitrobenzoic acid. The measurement of GSH was conducted according to the manufacturer's instructions. The GSH concentration in a sample can be determined by a fluorescence plate reader at Ex/Em = 340/420 and expressed as nmol per milligram protein. Protein content was measured by BCA method using bovine serum albumin as the standard. Mouse HSP70 (Abcam, Cambridge, UK) was used as an unconjugated control for cell-permeable HSP70 in this experiment.
Determination of contact hypersensitivity. Contact hypersensitivity experiments were performed as described previously [15] . For elicitation of CHS, female BALB/c mice (4 weeks old; Laboratory Animal Center Inc., Shizuoka, Japan) were sensitized by painting 100 ll of 3% 2,4,6-trinitro-1-chlorobenzene (TNCB, SigmaAldrich) in acetone/olive oil (4:1) on the shaved abdomens of the na€ ıve mice, and 6 days later, the right ear of each mouse was challenged by 20 ll of 1% TNCB on both front and back sides of the ear. CHS was determined by the degree of swelling of the TNCB-exposed ear compared with that of the vehicle-treated control ear on day 7 after challenge. Ear thickness was measured using a dial thickness gauge (Mitutoyo Corporation, Kanakawa, Japan). In brief, challenge with TNCB was done 6 days after sensitization, and ear swelling was measured 24 h later (Fig. 5a ).
Mice were randomly divided into four groups of 10 mice each. The groups were defined as follows: (1) a negative control group that was challenged with TNCB on the right ear without prior sensitization; (2) a positive control group that was sensitized and challenged by application of TNCB; (3) a HSP70-treated group that was treated with native HSP70 only on the ear and then treated with TNCB; and (4) a cell-permeable HSP70-treated group that was pretreated with 2 lM of cell-permeable HSP70 for 1 h on the right ear on day 6, followed by TNCB treatment on the same ear. All animal experiments were approved by the Yonsei University Institutional Review Board for animal studies.
Statistical analysis. Statistical analyses of mean values for multiple comparisons between different groups were carried out by one-way ANOVA with Turkey's honestly significant difference (HSD) test. All analyses were performed with SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism version 4.0 (GraphPad, San Diego, CA, USA). A P-value <0.05 was considered statistically significant.
Results

TNBS induced ROS production in XS-106 DCs
In the first set of experiments, we assayed the appropriate concentration of TNBS for toxicity. The concentration at which live cells (PI À /Annexin V À cells) exceeded 95% after 24 h was chosen for further experiments. TNBS did not affect the viability of XS-106 DCs at concentrations up to 50 lg/ml ( Figure S1 ). Next, we determined whether XS-106 DCs would produce ROS upon TNBS stimulation. After 30 min of TNBS treatment, ROS production increased significantly compared with controls in a dosedependent manner (Fig. 1) .
The HSP70 is a main carbonylated protein in TNBS-treated XS-106 DCs
The levels of TNBS-induced protein carbonylation were assayed by immunoblotting. When XS-106 DCs were treated with TNBS for 1-8 h, carbonylated proteins were detected by immunoblotting with anti-DNP antibody ( Fig. 2A) . DNP-modified proteins from XS-106 DCs treated with TNBS for 6 h were resolved by 1D-gel electrophoresis and excised from the gels for MALDI-TOF mass spectrometry (Fig. 2B) . Figure 2C shows the typical mass spectra of an excised band. Proteins were identified using the MASCOT search engine (Matrix Science, UK) to query the NCBI protein database. The main carbonylated protein was identified as HSP70 (estimated molecular weight (Mr), 71021; NCBI accession number gi|309319; Mascot score, 286; sequence coverage, 4%).
To confirm the carbonylation of HSP70, Western blotting for HSP70 in XS-106 DCs that were treated with 50 lg/ml of TNBS for 1-8 h was carried out. As shown in Fig. 2D , the treatment of TNBS depleted HSP70 in a time-dependent manner. This result shows that HSP70 was carbonylated and the amount of unaffected HSP70 decreased after treatment of TNBS in XS-106 DCs.
HSP70 transiently increased in cell-permeable HSP70-treated XS-106 DCs and inhibited ROS generation and protein carbonylation in TNBS-treated XS-106 DCs
To validate the role of HSP70 in TNBS-treated XS-106 DCs, we used a cell-permeable PTD (YARVRRRGPRR) from the human transcriptional factor Hph-1. HSP70 was transiently overexpressed in XS-106 DCs after treatment of cell-permeable HSP70. The level of HSP70 was elevated from 1 to 10 h compared with controls and returned to control levels after 12 h (Fig. 3A) .
To examine the effect of HSP70, XS-106 DCs were pretreated with 2 lM cell-permeable HSP70 1 h prior to 50 lg/ml TNBS treatment. Pretreatment with cell-permeable HSP70 decreased ROS production in XS-106 DCs (Fig. 3B) . After 12 h of pretreatment of cell-permeable HSP70, reduction in intracellular ROS production disappeared upon treatment with TNBS ( Figure S2 ). To determine the degree of inhibition of TNBS-induced ROS and protein carbonylation by cell-permeable HSP70, we quantified ROS using CM-H 2 DCFDA and flow cytometry and assayed carbonylation by immunoblotting. The pretreatment with PTD-HSP70 drastically reduced protein carbonylation in TNBS-treated XS-106 DCs. (Fig. 3C) . These results indicate that TNBS-induced ROS and protein carbonylation were downregulated by transiently overexpressed HSP70 in XS-106 DCs. To estimate the strength of the antioxidative effects, we compared cell-permeable HSP70 with GSH, a representative antioxidant. The GSH decreased ROS and protein carbonylation in TNBS-treated XS-106 DCs (Fig. 3B,C) . The antioxidative effect of cell-permeable HSP70 was as effective as that of GSH (Fig. 3C) .
Cell-permeable HSP70 reduced consumption of intracellular GSH in TNBS-treated XS-106 DCs
To better understand the antioxidant effects of the cell-permeable HSP70, we measured the change of intracellular GSH levels in TNBS-treated, unconjugated HSP70-TNBS-treated, cell-permeable HSP70-TNBS-treated XS-106 DCs and untreated XS-106 DCs (control), respectively. When the XS-106 DCs were treated with 50 lg/ml of TNBS, intracellular GSH levels decreased by 62% compared with untreated XS-106 DCs (P = 0.011). Similarly, the GSH level decreased by 56% in unconjugated HSP70-TNBS-treated XS-106 DCs. On the other hand, the GSH level decreased by only 15% in cellpermeable HSP70-TNBS-treated XS-106 DCs compared with the untreated control (Fig. 3D) . The level of GSH in both cell-permeable HSP70 and TNBS-treated XS-106 DCs was significantly higher than TNBS only-treated XS-106 DCs (P = 0.019). These results suggest that transiently increased HSP70 ameliorates the consumption of intracellular GSH in TNBS-treated XS-106 DCs.
HSP70 inhibited the activation of p38 MAPK and the production of IL-12 in TNBS-treated XS-106 DCs
In order to understand the functional relevance of TNBSinduced ROS, we measured the expression of p38 MAPK by immunoblotting and the level of IL-12 in the culture supernatants of XS-106 DCs by ELISA. As shown in Fig. 4A ,B, the level of p38 activation was 53% lower in cells pretreated with cell-permeable HSP70 (474.07 od/ mm) than controls (898.76 od/mm) after treatment with TNBS. The amount of downregulation of p38 by the transient overexpression of HSP70 was comparable to that of GSH pretreatment followed by TNBS treatment in XS-106 DCs (Fig. 4A,B) . The production of IL-12p70 significantly increased after 12 h of TNBS treatment (2645 pg/ml) compared with the control (650 pg/ml). This increase was abrogated by pre-incubation with cell-permeable HSP70 (1374 pg/ml) for 1 h and GSH (1706 pg/ml), respectively, indicating that the overexpression of intracellular HSP70 inhibited ............................................................................................................................................................... the production of IL-12 in XS-106 DCs treated with TNBS (Fig. 4C ).
Pretreatment of cell-permeable HSP70 suppressed TNCB-induced CHS in vivo
The role of HSP70 was evaluated in a murine model of CHS using the cell-permeable HSP70 protein (Fig. 5A ).
As shown in Fig. 5B , ear swelling in cell-permeable HSP70-treated mice (45.1 AE 2 mm 9 10 À2 ) was suppressed compared with that of TNCB-treated mice that were not pretreated (67.9 AE 2 mm 9 10 À2 ) with either HSP70 or cell-permeable HSP70. However, the pretreatment with native unconjugated HSP70 did not reduce TNCB-induced ear swelling (67.4 AE 2.1 mm 9 10 À2 ).
Discussion
The purpose of the present study was to examine the role of ROS in XS-106 DCs and to identify proteins affected by oxidative stress as well as their possible roles in CHS. We demonstrated that increased cellular levels of ROS caused the carbonylation of HSP70 in TNBS-treated XS-106 DCs using 1D-gel electrophoresis and MALDI-TOF mass spectrometric analysis. Moreover, the reduction in the unaffected form of HSP70 augmented the production of ROS in a glutathione-dependent pathway [16] . These results suggest a complementary role of HSP70 in the antioxidative system. In our experiments, the cell-permeable HSP70 successfully entered the cells, and the permeated HSP70 yielded transient overexpression of HSP70 in XS-106 DCs. The transiently increased intracellular level of HSP70 resulted in attenuated protein carbonylation, prevention of intracellular GSH depletion, downregulation of p38MAPK activation and IL-12 production. HSPs are physiologically induced in all cells by hyperthermia, an altered intracellular redox environment and exposure to heavy metals, amino acid analogs or cytotoxic drugs [17, 18] . HSPs are classically known to function as chaperones or proteases. They participate in the process of assembly, stabilization, folding and translocation of proteins, while as proteases, they are known to degrade damaged proteins [19] . In various environments, HSPs have been reported to be major endogenous cytoprotective molecules [20, 21] . HSP27 and HSP70, among all HSPs, are the most strongly induced after stresses such as oxidative stress, anticancer drugs or irradiation [22] . Increased levels of HSP70 in turn result in a marked increase in stress tolerance and cytoprotection [23] . Recently, many research groups have reported that HSP70 is cytoprotective under ischaemic conditions in many major organs such as brain, kidney or heart [24] [25] [26] [27] . Conversely, reduction in expression of HSPs can increase ROS generation and mitochondrial protein oxidation in TNBS-induced IL-12 secretion was abrogated by pre-incubation with cellpermeable HSP70 or with GSH. XS-106 DCs were pretreated with 2 lM of cell-permeable HSP70 and 2 mM of GSH for 1 h and then incubated with 50 lg/ml of TNBS for 24 h. The levels of IL-12 were measured in the supernatants of XS-106 DCs by ELISA. Error bars represent the mean AE SD of three independent experiments. We performed all analyses using one-way analysis of variance (ANOVA) with Turkey's HSD test for multiple comparisons.* P < 0.05, ** P < 0.01, *** P < 0.001; ns, not significant. GSH, Glutathione; PTD-HSP70, cell-permeable HSP70; TNBS, 2,4,6-trinitrobenzene sulphonic acid.
heat-shock factor-1-deficient mice [16] . Overexpression of HSP70 has also been shown to increase the cellular glutathione redox status, presumably by increasing the activities of glutathione peroxidase and glutathione reductase in kidney cells and intestinal mucosa [28] . However, to our knowledge, there have been no reports describing that HSP70 has a potent antioxidative effect comparable to that of GSH in CHS. The mechanisms by which HSP70 induces an antioxidative effect in CHS are still unclear; HSP70 may have a direct antioxidative effect or may increase the intracellular GSH level. In our study, the increased ROS resulted in activation of p38 MAPK and synthesis of IL-12 in XS-106 DCs. The p38 MAPK signalling pathway is important in the synthesis of IL-12 [29] although other complicated signalling pathways, such as phosphoinositide 3-kinase and cyclic AMP pathway, also take part in the regulation of IL-12 synthesis [30] [31] [32] .
IL-12 stimulates naive CD4+ T cells to differentiate into Th1 cells [33] . Considering that allergic contact dermatitis is a classic example of Th1-mediated delayed-type hypersensitivity [34] , our results suggest that ROS may play an essential role in the pathogenesis of CHS [7, 35] . Moreover, very recent study showing attenuation of CHS by topical pretreatment with various antioxidants stresses the importance of ROS in CHS [36] .
Our results indicate that hapten activates p38 MAPK partly through the production of ROS. Mammalian p38 are activated by a wide range of cellular stress [37, 38] . Earlier investigations have observed a connection between ROS production and MAPKs activation by heat shock [39] . Increased ROS by heat shock can activate p38, which plays an essential role in upregulation of inflammatory mediators [40] . There are several reports supporting the connections between ROS and p38 in CHS [40, 41] . Here, we offer additional evidence of the links among hapten, ROS production and ROS-mediated activation of p38.
Our results suggest that ROS and HSP70 may exert mutual control. Overexpression of ROS may induce carbonylation of HSP70 and interfere with the function of the antioxidative effect of HSP70. Conversely, increased intracellular HSP70 may decrease ROS and the secondary immune response in CHS. In CHS, hapten-induced ROS depletes HSP70 by carbonylation, which in turn produces more ROS. This vicious cycle can maintain the pathologic condition in CHS by persistent expression of a downstream mediator, such as IL-12.
The diverse actions of HSP70 have resulted in conflicting findings of its pathogenic role in CHS. Yusuf et al. [42] reported that topically applied anti-HSP70 antibody had a suppressive effect on CHS by inhibition of inflammatory cytokines. Although HSP70 was found intracellularly, the secreted extracellular form of HSP70 was also recognized [43, 44] . Secreted HSP70 is capable of binding to antigenic peptides and delivering them to DCs in a receptormediated manner [45, 46] . Judging from both the cytoprotective and antioxidative roles of intracellular HSP70 and the immunostimulatory action by the extracellular form, HSP70 likely acts like a double-edged sword in the pathogenesis of CHS.
In summary, ROS production was significantly increased after treatment with TNBS in XS-106 DCs. TNBS-treated XS-106 DCs showed increased protein carbonylation. The major carbonylated protein was HSP70, which was identified by MALDI-TOF analysis. The na€ ıve form of HSP70 was decreased in TNBS-treated XS-106 DCs through carbonylation. In vitro, TNBSinduced ROS, p38 MAPK activation and IL-12 production were downregulated in HSP70-overexpressed XS-106 DCs. Although immunomodulatory action of cell-permeable HSP70 in mouse model was discussed in our previous study [47] , the attenuation of CHS by cell-permeable HSP70 may be explained from the antioxidative effect of A B Figure 5 Cell-permeable HSP70-treated mice demonstrated a downregulated contact hypersensitivity (CHS) response. (A) CHS procedure. Groups of control (n = 5) and HSP70-treated mice (n = 5) were sensitized with 3% TNCB on the shaved abdomen and challenged by application of 1% TNCB on both sides of the right ear 6 days later. (B) Suppressed ear swelling in cell-permeable HSP70 pretreated mice. The CHS reaction to TNCB is represented as incremental ear swelling at 24 h after challenge (on day 7). Mice that were not sensitized to TNCB exhibited no ear swelling with challenge. Cell-permeable HSP70-treated mice showed significantly abrogated CHS responses compared with untreated TNCB-sensitized mice or HSP70-treated mice. These data are representative of three independent experiments. We performed the analysis using ANOVA with Turkey's HSD test for multiple comparisons. ***P < 0.001. PTD-HSP70, cell-permeable HSP70; TNCB, 2,4,6-trinitro-1-chlorobenzene.
HSP70. On the basis of our results, we propose that HSP70-targeting therapy would be effective in controlling CHS. Our results also indicate that antioxidants that can break out of a ROS-driven vicious cycle seem to be useful in the control of CHS.
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